Century Therapeutics, Inc.
NCM: IPSCLive Quote
📈 ZcoreAI Score
Our AI model analyzes Century Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get IPSC Z-Score →About Century Therapeutics, Inc.
Healthcare
Biotechnology
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
📊 Fundamental Analysis
Century Therapeutics, Inc. demonstrates a profit margin of -8.8%, which is below the sector average, suggesting competitive pressure.
The company recently reported -100.0% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -6.0%, which indicates that capital utilization is currently under pressure.
At a current price of $2.25, IPSC currently sits at the 70th percentile of its 52-week range (Range: $0.43 - $3.04).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$404.38M
Trailing P/E
--
Forward P/E
-4.25
Beta (5Y)
1.67
52W High
$3.04
52W Low
$0.43
Avg Volume
1.46M
Day High
Day Low